Effect of omeprazole on the concentration of interleukin-6 and transforming growth factor-β1 in patients receiving dual antiplatelet therapy after percutaneous coronary intervention

European Cytokine Network

Volumn 21, Issue 4, 2010, Pages 257-263

  Hudzik, Bartosz ^a   Szkodzinski, Janusz ^a   Danikiewicz, Aleksander ^a   Wilczek, Krzysztof ^a   Romanowski, Wojciech ^a   Lekston, Andrzej ^a   Polonski, Lech ^a   Zubelewicz Szkodzinska, Barbara ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Clopidogrel; Interleukin 6; Omeprazole; Transforming growth factor 1

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; INTERLEUKIN 6; OMEPRAZOLE; TRANSFORMING GROWTH FACTOR BETA1;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; DRUG EFFECT; DRUG FATALITY; FEMALE; FOLLOW UP; HEART DISEASE; HOSPITAL READMISSION; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; LOADING DRUG DOSE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION AND FORECASTING; PROTEIN BLOOD LEVEL; RISK; SENSITIVITY AND SPECIFICITY; STROKE;

AGED; ANTI-ULCER AGENTS; ASPIRIN; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; OMEPRAZOLE; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; TICLOPIDINE; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME;

EID: 78650479547     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2010.0213     Document Type: Article

References (28)

1. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group. N Engl J Med 1994; 331: 489-95.
2. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501.
3. Celinski K, Cichoz-Lach H, Madro A, Slomka M, Kasztelan- Szczerbinska B, Dworzanski T. Non-variceal upper gastrointestinal bleeding - guidelines on management. J Physiol Pharmacol 2008; 59 (Suppl. 2): 215-29.
4. Gurbel PA, Tantry US. Drug insight: Clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med 2006; 3: 387-95.
5. Antonino MJ, Mahla E, Bliden KP, Tantry US, Gurbel PA. Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. Am J Cardiol 2009; 103: 1546-50.
6. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-60.
7. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
8. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006; 4: 2508-9.
9. Ridker PM, Rifai N, Stampfer MJ, Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.
10. Szkodzinski J, Blazelonis A, Wilczek K, et al. The role of interleukin-6 and transforming growth factor-ß1 in predicting restenosis within stented infarct-related artery. Int J Immunopathol Pharmacol 2009; 22: 493-500.
11. Karpinski L, Plaksej R, Kosmala W, Witkowska M. Serum levels of interleukin-6, interleukin-10 and C-reactive protein in relation to left ventricular function in patients with myocardial infarction treated with primary angioplasty. Kardiol Pol 2008; 66: 1279-85.
12. Van Snick J. Interleukin-6 an overview. Annual Rev Immunol 1990; 8: 253-78.
13. Wong GG, Clark SC. Multiple actions of IL-6 within a cytokine network. Immunology Today 1988; 9: 137-9.
14. Marie C, Cavaillon JM. Negative feedback in inflammation. The role of anti-inflammatory cytokine. Bulletin de l'Institut Pasteur 1997; 95: 141-54.
15. Hudzik B, Szkodzinski J, Romanowski W, et al. No predictive value of serum interleukin-6 and transforming growth factor-ß1 in identifying patients with a first restenosis, recurrent restenosis or a history of restenosis. Eur Cytokine Netw 2009; 20: 135-9.
16. Bhatt DL, Scheiman J, Abraham NS, et al. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52: 1502-17.
17. Aubert RE, Epstein RS, Teagarden JR, et al. Proton Pump Inhibitors Effect on Clopidogrel Effectiveness: The Clopidogrel Medco Outcomes Study. Circulation 2008; 118: S-815 (Abstract 3998).
18. Jakubowski A, Chlopicki S, Olszanecki R, et al. Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 139-45.
19. Ziemianin B, Olszanecki R, Uracz W, Marcinkiewicz E, Gryglewski RJ. Thienopyridines: effects on cultured endothelial cells. J Physiol Pharmacol 1999; 50: 597-604.
20. Gryglewski RJ. Prostacyclin among prostanoids. Pharmacol Rep 2008; 60: 3-11.
21. Yang J, Shi D, Yang D, Song X, Yan B. Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2. Mol Pharmacol 2007; 72: 686-94.
22. Gurbel PA, Bliden KP, Kreutz RP, Dichiara J, Antonino MJ, Tantry US. The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting. Platelets 2009; 20: 97-104.
23. Juurlink DN, Gomes T, Ko DT, et al. Mamdani MM. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-8.
24. Dunn SP, Macaulay TE, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008;118:S815.
25. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148.e1-5.
26. Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 821-7.
27. Fontana P, Dupont A, Gandrille S, et al. Adenosine diphosphateinduced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-95.
28. Würtz M, Grove EL, Kristensen SD, Hvas AM. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 2010; 96: 368-71.